Ibrahim Alsaadi MD

استشاري أمراض القلب وقسطرة القلب التداخلية

[Ibrahim Alsaadi MD @ibalsaadi]

@ayedhalamri الف مبروك موفق باذن الله

[Ibrahim Alsaadi MD @ibalsaadi]

Interesting case
Defer ad-hoc PCI as the patient is stable and STE resolved
Admit to CCU for anti thrombotic and anti platelets DAPT
reschedule him for IVUS during same admission to evaluate thrombotic resolution
Or optimize medical therapy
If the aneurysm >20 mm or > 3 of the reference vessel or unsuitable for covered stent call the CS for surgical ligation

[MIЯVΛƬ #IC ༄ ｡° @mirvatalasnag]

The heart team is never complete without these fantabulous men & women

@Tesslagra @baileyannRN @RadialFirstBot @TAVRBot

[Ibrahim Alsaadi MD @ibalsaadi]

كأول عملية تجرى بمحافظة الطائف و بقيادة رئيس الجمعية السعودية للقسطرة الدكتور وائل قشقري @AlkashkariWail قام الفريق الطبي بمركز القلب بحمدالله بإجراء قسطره لسد ثقب بين الاذين الايمن والايسر لمريضه ثلاثينية في مستشفى الملك عبدالعزيز التخصصي @kaashtaif بالطائف وتكللت بحمدالله بالنجاح.
@mirvatalasnag @SACIS_KSA @assiri99 @DrTalal_Almalki @bogamisa @DrAlsaiediAB @Falmutairi2018 @SaudiMOH @TaifHCluster @Dr_ShazaAlalawi @DrAlsubei @DAbdullahSharaf

[Abdulrahman Abdu @abdulrhmanmabdu]

ابارك لبلدي هذا الانجاز الكروي وابارك لأبوي وأخوي بدر ولكل اهلاوي بطولة النخبة الآسيوية. تستاهلوها 💚💚

[مساعد الرشيدي @Msa3dAlrshedi]

لا فاز الاهلي تنام الارض مبسوطه
العشب سر ابتسامتها .. وفرحتها

[Rabeh Saqer رابح صقر @RabehSaqer]

https://t.co/mNe6jnk18Uمبرووووك يا أهلي🇸🇦💚🤍تستاهلون الكأس🙏

[Ibrahim Alsaadi MD @ibalsaadi]

ظلم تحكيمي فاضح
هدف غير شرعي
طرد لعلي مجرشي غير مستحق
ضربتين جزاء دفع لايبانيز و دفع لرياض لم تحتسب
الحكم ؟؟!!!!
#الأهلي_جوهور_دار_التعظيم

[Ibrahim Alsaadi MD @ibalsaadi]

@MichaelAlbertMD I am also taking rosuvastatin ,ezetimibe and evolocumab
I have strong family hx of premature CAD
My LDL was 6.1 now 0.47
No symptoms

[Lucrecia M. Burgos, MD @lucreciamburgos]

🚨 CADENCE Trial — #ACC26
We have encouraging results from one of the most anticipated clinical trials at #ACC26
Sotatercept in patients with HFpEF and combined post- and precapillary pulmonary hypertension
🔑 Key findings:
• Significant reduction in pulmonary vascular resistance
• Improvements in mPAP and PAWP
• Better functional capacity (6MWD)
• Signals toward reduced clinical worsening
🧠 A promising new pathway targeting pulmonary vascular and cardiac remodeling
👀 Could this open a new era in HFpEF management?

[Ritu Thamman MD @iamritu]

ORBITA-CTO #ACC26

СТО PCI reduced angina frequency (immediate consistent & sustained)

Excellent experienced operators, 25% pts had JC score 3 (difficult) CTO ,similar antianginal use in both groups( post pci angina, micro vascular dz, non cad pain?)

[Shariq Shamim @ShariqShamimMD]

#ACC26 Much awaited Door to Unload trial for Anterior MI failed to show the benefit for Impella. Unload before Revasc for Ant MI. Surprisingly mean BP ~140 despite LVEDP in high 20s!

[Dr. Purvi Parwani @purviparwani]

CADENCE #ACC26

🧑‍⚕️ HFpEF patients with combined post- and pre-capillary pulmonary hypertension —a high-risk group with no approved therapies
🧠Targeting activin signaling with sotatercept would improve pulmonary vascular disease and hemodynamics
📊 Primary result: Met primary endpoint → significant reduction in pulmonary vascular resistance (PVR)
📉Improvements in PAWP, exercise capacity, and other hemodynamics, suggesting both pulmonary + cardiac benefit
💡 First real signal that we can treat pulmonary vascular disease in HFpEF—not just manage symptoms

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

Management of intermediate–high-risk PE remains a major clinical challenge.

🎷HI-PEITHO tests catheter-directed thrombolysis vs anticoagulation alone.

Will this change how we escalate therapy in PE?

➡️ Key results:
🎷544 patients randomized w/ intermediate Risk PE- 43% female, mean age 58
🎷Anti CoAg 🆚 thrombolysis
🎷outcome: PE mortality/PE recurrence
💥Favored Catheter directed thrombolysis for PE: Relative Risk 0.39
⤵️ Hospital stay
⤴️ Bleeding but no diff in major bleeding
#ACC26 #PulmonaryEmbolism #Cardiology

@NEJM
📎 https://t.co/wbrSDsVsXj

[MIЯVΛƬ #IC ༄ ｡° @mirvatalasnag]

@PCRonline #ACC2026

ALL RISE: FFRangio is noninferior to pressure-wire–guided assessment in ⬇️ risk in intermediate coronary stenoses

https://t.co/bFQ3xOr4Mj

@nejm 👉 https://t.co/nBjvYx224I

@wfearonmd @rallamee @DrAmirKaki @djc795 @kalazizimd @LouaiRazzouk @rwyeh @RajTayalMD

[Zille Huma @Zill_cardio]

Chest Pain But No Obstructive Coronary Arteries...

Solving the Mystery Through Assessment of Microvascular Disease, Spasm and Myocardial Bridging 👇

#ANOCA #MVD #CoronarySpasm #MyocardialBridging @ACCinTouch @JACCJournals

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

CHIP-BCIS3 evaluates LV unloading strategies in complex PCI

Can mechanical support improve outcomes in stable elective pci?

➡️ Key results:
Use of unloading with microaxial flow pump did not improve outcomes and was associated with ⤴️ CV deaths I. Patients with severe LV dysfunction undergoing complex PCI

83% Male
#ACC26 #PCI #CardioTwitter #LBCT @NEJM @mmamas1973

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

Do we still need pressure wires to guide PCI?

#ALLRISE trial compares angiography-derived physiology vs wire-based assessment.

Is FFRangio better than a pressure wire approach? Is it ready for prime time?

➡️ Key results:
🎷FFRangio 🆚 pressure wire: shorter time of procedure and same MACE outcomes at 1 year
🎷 Shorter time, ⤵️ fluoro ⤵️ contrast use

25% 💃🏻
#ACC26 #PCI #LBCT #CardioTwitter @NEJM
📎 https://t.co/ikH9K5gFUI

[Ibrahim Alsaadi MD @ibalsaadi]

بين يومٍ أنت حاضر فيه… ويومٍ تغيب فيه، يظهر صدق النيّة كما هو، بلا زينةٍ ولا ادّعاء
فكم من اسمٍ علا حين خدم، ثم خبا حين استأثر،
وكم من أثرٍ صامتٍ بقي، لأن صاحبه مرّ خفيفًا… وأثقل الميزان.
ليست الحكاية في الوصول، بل في ما تتركه خلفك؛
فالطريق ينسى العابرين، ولا ينسى من مهّدوه

[منسوبي وزارة الصحة @e_mohcom]

تكليف الأستاذ / محمد بن حمزة سندي بأعمال ومهام الرئيس التنفيذي لـ #تجمع_الطائف_الصحي لمدة عام اعتباراً من 1447/10/20هـ .